search
for
 About Bioline  All Journals  Testimonials  Membership  News


Indian Journal of Human Genetics
Medknow Publications on behalf of Indian Society of Human Genetics
ISSN: 0971-6866
EISSN: 0971-6866
Vol. 8, No. 2, 2002, pp. 69-72
Bioline Code: hg02014
Full paper language: English
Document type: Research Article
Document available free of charge

Indian Journal of Human Genetics, Vol. 8, No. 2, 2002, pp. 69-72

 en The Micronucleus Test in Urothelial Cells of Cervix Cancer Patients
Gursatej Gandhi, Pankaj Sharma

Abstract

Cervix cancer continues to be a common malignancy in Indian women in the absence of routine cervix examination. Most cases come to light as referrals of advanced gynecologic complaints. It was proposed to look for micronuclei in bladder cells (as a non-invasive method) of such women subsequently diagnosed with cervix cancer. Urine samples of just diagnosed cancer patients (n=25; 21-80 yrs) and of controls (with other gynecological problems; n=25; 21-70 yrs) were processed for the micronucleus test using standard protocols.

Significantly elevated frequency of cells with micronuclei was observed in 72% of the patients as compared to that among controls (16.7%). Percent frequencies of micronucleated cells were highest in patients in stage III; in older patients; in those with younger ages-at-marriage; who had highest number of pregnancies; and were of low socio-economic status. The test in urothelial cells indicates damage in a tissue, which is not the site where cervix cancer develops. As it utilizes a non-invasive procedure of sampling, if validated it may find use in mass screening of cervix cancer.

Keywords
micronuclei, uterine cancer, bladder cells

 
© Copyright 2002 - The Indian Society of Human Genetics
Alternative site location: http://www.ijhg.com/

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil